

Samuel Munguia

TMP 120

Professor Michael-James Hey

4/13/2021

	PFE YE 2020	AZN YE 2020	MRNA YE 2020		PFE		AZN		MRNA	
	Largest	Middle	Smallest		2019 YE	2018 YE	2019 YE	2018 YE	2019 YE	2018 YE
Market Cap \$Bn	207	129	59		216	249	130	94	6	5
Stock Price \$	37	49	147		36	40	50	37	19	14
Revenue \$	41B	26B	803M		51B	53B	24B	22B	60M	135M
Gross Margin	33B/41B 80.4%	21B/26B 80.7%	795M/803M 99%		41B/51B 80.3%	42B/53B 79.2%	19.4B/24B 80.8%	17.1B/22B 77.7%	N/A	N/A
Operating Margin	8.7B/41B 19.7%	3.6B/26B 13.8%	-763M/803M -95%		13.9B/51B 27.2%	15B/53B 28.3%	1.7B/24B 7%	1.5B/22B 6.8%	-545M/60M -908%	-413M/135M -305%
Net Profit Margin	9.6B/41B 22.1%	3.1B/26B 11.9%	-747M/803M -93%		16.2B/51B 31.7%	11.1B/53B 20.9%	1.3B/24B 5.4%	2.1B/22B 9.5%	-514M/60M -856%	-384M/135M -284%
Current Ratio	35B/25B 1.4	19B/20B 0.95	6.2B/4.3B 1.44		32B/37B .87	49B/31B 1.5	15B/18B .83	15B/16B .93	1.1B/143M 7.69	1.5B/222M 6.75
Long Term Debt to Equity Ratio	64.8B/63.4 B 1.02	30.7B/15.6 B 1.96	386M/2.5B 0.15		66B/63B 1.04	63B/63B 1.00	28B/14B 2.00	30B/14B 2.14	271M/1.1B 0.24	209M/1.5B 0.13

Notes:

- Pfizer's Market Cap is almost twice the size of AstraZeneca and about 4 times the size of Moderna.
- Moderna announced an IPO in Dec. 2018 and from 2018-2019 its Stock Price is much lower than its competitors but for year 2020 Moderna blew its competitors out the water with its Stock Price surging to \$147! (Here's an interesting link [if you had invested in Moderna back in 2018](#))

- Moderna's Gross Margin for 2018-2019 is N/A because [Yahoo Finance](#) does not have Cost of Revenue nor Gross Profit listed.
- Moderna's revenue and market cap has been soaring since 2019 but its competitors have been struggling to show growth.
- Moderna has maintained a negative Operating Margin and a negative Net Profit Margin but it also has maintained a good Long-Term Debt to Equity Ratio unlike its competitors.
- AstraZeneca's Current Ratio throughout the years is the worst compared to its competitors in the table above.